An effortless and comprehensive approach to burden of illness reviews

Blog - HEORO 2020 Review

Published: 07-01-2021

We added 17,200 abstracts to our database throughout the year, a total of 6,188 were published in 2020.


Papers added to our database this year (published any year)


2,062 economic evaluations and 2,493 mortality studies were added to our database in 2020, which were published in 2019.

7% of abstracts included utility value data. With 151 new tools being added to our ontology, 54 of which assessed quality of life in caregivers of children. Some of the newly added tools are listed below:


Social Appearance Anxiety Scale (SAAS)  Fruit And Vegetable VAriety index (FAVVA). Occupational Value Assessment questionnaire
Self-Assessment Manikin scale Fatigue Symptom Inventory Relatives' Stress scale
Ryff's Psychological Wellbeing Scale General symptom Questionnaire, GSQ Fami-Life questionnaire
Boston Bowel Preparation Scale (BBPS) score Readiness for Hospital Discharge Scale (RHDS) brief parenting scale (PS-7)
Functional Difficulties Questionnaire Charleston Psychiatric Outpatient Satisfaction Scale CPOSS Family Assessment Device (GF-FAD)
Heartland Forgiveness Scale Health Care Relationship (HCR) Trust scale Parent Report of Children's Abilities-Revised (PARCA-R)
Interpersonal Reactivity Index-C Patient's Questionnaire on Participation in Discharge Planning  Cochlear Implant Quality of Life (CIQOL)
Psychosocial Adjustment and Role Skills Scale Stress Response Questionnaire (SRQ) Eustachian Tube Dysfunction Questionnaire (ETDQ-7)
Body Awareness Questionnaire  Kasari Frequency Intensity Time (FIT) index Women's Ischemia Symptom Questionnaire (WISQ)
Adult Dispositional Hope Scale Workplace Activity Limitations Scale (WALS) Adolescent Pediatric Pain Tool


69 new interventions were added from January to September, all are listed below:


Semaglutide  Guadecitabine Ianalumab Tucatinib Zolbetuximab Moxetumomab pasudotox
Ipragliflozin Pracinostat Caplacizumab Apabetalone Opicinumab Ivosidenib
Ertugliflozin Lobaplatin Utidelone Peficitinib Pyrotinib Utomilumab
Praliciguat  B-cell antagonists Zanubrutinib Dalantercept Enfortumab vedotin Orvepitant
Nerinetide HER-3 inhibitors Emicizumab Afuresertib Guselkumab Tislelizumab
Avibactam Focal adhesion kinase inhibitors Brigatinib Poziotinib Ripretinib Surufatinib
Letermovir  Palmitoylethanolamide Anifrolumab Roniciclib Polatuzumab Vedotin Tarextumab
Glecaprevir  Icodextrin Teprotumumab Depatuxizumab mafodotin Ibalizumab Tirabrutinib
pibrentasvir  Pitolisant Alisertib Clazosentan Lazertinib Omadacycline
Dengue vaccine Emibetuzumab Patritumab Mogamulizumab Pamrevlumab
COVID-19 vaccine imidafenacin Defactinib Lorlatinib Olaptesed pegol 
Melflufan Darvadstrocel Brentuximab vedotin Enasidenib Lanadelumab 



550 abstracts added to Heoro focused on COVID-19, which was the only disease added to our ontology list. Cost and recourse use and mortality studies were the most common, as seen in figure 1.

 Figure 1 - Study types of 2020 publications added to HEORO which focused on COVID-19.

Figure 1 - Study types of abstracts added to HEORO which focused on COVID-19



Papers added to our database only published in 2020


The most common study type was cost and resource use (2180 publications), followed by mortality studies (1534 publications), PRO studies (1305 publications) and Economic models (991 publications). This is represented in Figure 2.

Regarding study methodology, we added 839 abstracts of randomized controlled trials and 840 systematic literature reviews. 



Figure 2 - study type of papers published in 2020 on Heoro


Abstracts originated from 133 countries, with the USA (2059 publications) and the United Kingdom (1015 publications) being the highest, as seen in Figure 3.


Most abstracts were from Europe (2600 publications) followed by North America (2441), Asia (833 publications), Africa (328 publications) and South America (275 publications).


Figure 3 - abstracts by country added to Heoro


Finally, the abstracts most commonly reported on adult populations (figure 4). 



Figure 4 - abstracts published in 2020 by study population




Here's to an even better 2021 on!



Holly Gould